The phosphodiesterase-4 inhibitor rolipram reverses Aβ-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats

International Journal of Neuropsychopharmacology

Volumn 15, Issue 6, 2012, Pages 749-766

  Wang, Chuang ^a,b   Yang, Xue Mei ^a   Zhuo, Ye Ye ^a   Zhou, Heng ^a   Lin, Huan Bing ^a   Cheng, Yu Fang ^a   Xu, Jiang Ping ^a   Zhang, Han Ting ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

CREB; memory; phosphodiesterase 4 (PDE4); rolipram; amyloid (A )

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN BCL 2; ROLIPRAM;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AVOIDANCE BEHAVIOR; BRAIN REGION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; EXPLORATORY BEHAVIOR; HIPPOCAMPUS; LEARNING DISORDER; MALE; MAZE TEST; MEMORY; NERVOUS SYSTEM INFLAMMATION; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

EID: 84862139251     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711000836     Document Type: Article

References (130)

1. Abdi A, Sadraie H, Dargahi L, Khalaj L, et al. (2010). Apoptosis inhibition can be threatening in Ab-induced neuroinflammation, through promoting cell proliferation. Neurochemical Research 36, 39-48.
2. Agostinho P, Cunha RA, Oliveira C (2010). Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Current Pharmaceutical Design 16, 2766-2778.
3. Ahn J, Um M, Choi W, Kim S, et al. (2006). Protective effects of Glycyrrhiza uralensis Fisch on the cognitive deficits caused by beta-amyloid peptide 25-35 in young mice. Biogerontology 7, 239-247.
4. Ariga M, Neitzert B, Nakae S, Mottin G, et al. (2004). Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. Journal of Immunology 173, 7531-7538. (Pubitemid 39628194)
5. Bailey CH, Bartsch D, Kandel ER (1996). Toward a molecular definition of long-term memory storage. Proceedings of the National Academy of Sciences USA 93, 13445-13452. (Pubitemid 26424140)
6. Barad M, Bourtchouladze R, Winder DG, Golan H, et al. (1998). Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proceedings of the National Academy of Sciences USA 95, 15020-15025. (Pubitemid 29003749)
7. Barnham KJ, Masters CL, Bush AI (2004). Neurodegenerative diseases and oxidative stress. Nature Reviews Drug Discovery 3, 205-214.
8. Boissard CG, Lindner MD, Gribkoff VK (1992). Hypoxia produces cell death in the rat hippocampus in the presence of an A1 adenosine receptor antagonist : an anatomical and behavioral study. Neuroscience 48, 807-812.
9. Borner C (2003). The Bcl-2 protein family : sensors and checkpoints for life-or-death decisions. Molecular Immunology 39, 615-647. (Pubitemid 35454076)
10. Bounhar Y, Zhang Y, Goodyer CG, LeBlanc A (2001). Prion protein protects human neurons against Bax-mediated apoptosis. Journal of Biological Chemistry 276, 39145-39149.
11. Bourtchouladze R, Lidge R, Catapano R, Stanley J, et al. (2003). A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proceedings of the National Academy of Sciences USA 100, 10518-10522. (Pubitemid 37071910)
12. Bradl M, Hohlfeld R (2003). Molecular pathogenesis of neuroinflammation. Journal of Neurology, Neurosurgery, and Psychiatry 74, 1364-1370.
13. Burgin AB, Magnusson OT, Singh J, Witte P, et al. (2010). Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 28, 63-70.
14. Cammarota M, Bevilaqua LR, Dunkley PR, Rostas JA (2001). Angiotensin II promotes the phosphorylation of cyclic AMP-responsive element binding protein (CREB) at Ser133 through an ERK1/2-dependent mechanism. Journal of Neurochemistry 79, 1122-1128. (Pubitemid 34019791)
15. Cheng G, Whitehead SN, Hachinski V, Cechetto DF (2006). Effects of pyrrolidine dithiocarbamate on beta-amyloid (25-35)-induced inflammatory responses and memory deficits in the rat. Neurobiology of Disease 23, 140-151. (Pubitemid 43903636)
16. Cheng YF, Wang C, Lin HB, Li YF, et al. (2010). Inhibition of phosphodiesterase-4 reverses memory deficits produced by Ab25-35 or Ab1-40 peptide in rats. Psychopharmacology (Berlin) 212, 181-191.
17. Christensen R, Marcussen AB, Wörtwein G, Knudsen GM, et al. (2008). Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT(2A) levels. Experimental Neurology 210, 164-171. (Pubitemid 351258077)
18. Conti M, Richter W, Mehats C, Livera G, et al. (2003). Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. Journal of Biological Chemistry 278, 5493-5496. (Pubitemid 36800786)
19. Dastidar SG, Ray A, Shirumalla R, Rajagopal D, et al. (2009). Pharmacology of a novel, orally active PDE4 inhibitor. Pharmacology 83, 275-286.
20. De A, Boyadjieva NI, Pastorcic M, Reddy BV, et al. (1994). Cyclic AMP and ethanol interact to control apoptosis and differentiation in hypothalamic beta-endorphin neurons. Journal of Biological Chemistry 269, 26697-26705. (Pubitemid 24982930)
21. Delobette S, Privat A, Maurice T (1997). In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat. European Journal of Pharmacology 319, 1-4. (Pubitemid 27051308)
22. Demuro A, Parker I, Stutzmann GE (2010). Calcium signaling and amyloid toxicity in Alzheimer disease. Journal of Biological Chemistry 285, 12463-12468.
23. Dhitavat S, Ortiz D, Shea TB, Rivera ER (2002). Acetyl-L-carnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels. Neurochemical Research 27, 501-505.
24. Di Bona D, Scapagnini G, Candore G, Castiglia L, et al. (2010). Immune-inflammatory responses and oxidative stress in Alzheimer' disease : therapeutic implications. Current Pharmaceutical Design 16, 684-691.
25. Dimmeler S, Breitschopf K, Haendeler J, Zeiher AM (1999). Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. Journal of Experimental Medicine 189, 1815-1822. (Pubitemid 29272698)
26. Donnell AF, Dollings PJ, Butera JA, Dietrich AJ, et al. (2010). Identification of pyridazino[4,5-b] indolizines as selective PDE4B inhibitors. Bioorganic & Medicinal Chemistry Letters 20, 2163-2167.
27. Dorr J, Roth K, Zurbuchen U, Deisz R, et al. (2005). Tumor-necrosis- factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate. Journal of Neuroimmunology 167, 204-209. (Pubitemid 41242303)
28. Genain CP, Roberts T, Davis RL, Nguyen MH, et al. (1995). Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proceedings of the National Academy of Sciences USA 92, 3601-3605.
29. Giorgi M, Modica A, Pompili A, Pacitti C, et al. (2004). The induction of cyclic nucleotide phosphodiesterase 4 gene (PDE4D) impairs memory in a water maze task. Behavioral Brain Research 154, 99-106. (Pubitemid 39070457)
30. Gong B, Vitolo OV, Trinchese F, Liu S, et al. (2004). Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. Journal of Clinical Investigation 114, 1624-1634. (Pubitemid 40385553)
31. Gong QH, Pan LL, Liu XH, Wang Q, et al. (2011). S-propargyl-cysteine (ZYZ-802), a sulphur-containing amino acid, attenuates beta-amyloid-induced cognitive deficits and pro-inflammatory response: involvement of ERK1/2 and NF-kappaB pathway in rats. Amino Acids 40, 601-610.
32. Griebel G, Misslin R, Vogel E, Bourguignon JJ (1991). Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors. Pharmacology Biochemistry & Behavior 39, 321-323.
33. Hardy J (1997). Amyloid, the presenilins and Alzheimer's disease. Trends in Neurosciences 20, 154-159. (Pubitemid 27116286)
34. Hardy J, Selkoe DJ (2002). The amyloid hypothesis of Alzheimer's disease : progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
35. Haupt Y, Rowan S, Shaulian E, Kazaz A, et al. (1997). p53 mediated apoptosis in HeLa cells : transcription dependent and independent mechanisms. Leukemia 3, 337-339.
36. Holscher C, Gengler S, Gault VA, Harriott P, et al. (2007). Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. European Journal of Pharmacology 561, 85-90. (Pubitemid 46435857)
37. Houslay MD, Adams DR (2003). PDE4 cAMP phosphodiesterases : modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochemical Journal 370, 1-18. (Pubitemid 36259414)
38. Hoyle GW (2010). Mitigation of chlorine lung injury by increasing cyclic AMP levels. Proceedings of the American Thoracic Society 7, 284-289.
39. Imanishi T, Sawa A, Ichimaru Y, Miyashiro M, et al. (1997). Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. European Journal of Pharmacology 321, 273-278. (Pubitemid 27105928)
40. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, et al. (2002). Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. Journal of Neuroscience 22, 2246-2254. (Pubitemid 35386524)
41. Jin DQ, Park BC, Lee JS, Choi HD, et al. (2004). Mycelial extract of Cordyceps ophioglossoides prevents neuronal cell death and ameliorates beta-amyloid peptide-induced memory deficits in rats. Biological Pharmaceutical Bulletin 27, 1126-1129.
42. Jin SL, Conti M (2002). Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proceedings of the National Academy of Sciences USA 99, 7628-7633. (Pubitemid 34568742)
43. Karsan A, Yee E, Poirier GG, Zhou P, et al. (1997). Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. American Journal of Pathology 151, 1775-1784. (Pubitemid 27527940)
44. Kast RE (2000). Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMP. International Journal of Immunopharmacology 22, 1001-1006.
45. Kim DH, Kim S, Jeon SJ, Son KH, et al. (2008). The effects of acute and repeated oroxylin A treatments on Abeta(25-35)-induced memory impairment in mice. Neuropharmacology 55, 639-647.
46. Kim JE, Song SE, Kim YW, Kim JY, et al. (2010). Adiponectin inhibits palmitate-induced apoptosis through suppression of reactive oxygen species in endothelial cells : involvement of cAMP/protein kinase A and AMP-activated protein kinase. Journal of Endocrinology 207, 35-44.
47. Koriyama Y, Chiba K, Mohri T (2003). Propentofylline protects beta-amyloid protein-induced apoptosis in cultured rat hippocampal neurons. European Journal of Pharmacology 458, 235-241. (Pubitemid 36009462)
48. Korsmeyer SJ (1992). Bcl-2 : a repressor of lymphocyte death. Immunology Today 13, 285-288.
49. Korsmeyer SJ, Yin XM, Oltvai ZN, Veis-Novack DJ, et al. (1995). Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Biochimical et Biophysica Acta 1271, 63-66.
50. Krause W, Kuhne G (1988). Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica 18, 561-571.
51. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA (2001). Possible new role for NF-kappaB in the resolution of inflammation. Nature Medicine 7, 1291-1297. (Pubitemid 34007932)
52. Lesort M, Terro F, Esclaire F, Hugon J (1997). Neuronal APP accumulates in toxic membrane blebbings. Journal of Neural Transmission 1104, 497-513. (Pubitemid 27379905)
53. Li B, Dou QP (2000). Bax degradation by the ubiquitin/proteasome- dependent pathway: involvement in tumor survival and progression. Proceedings of the National Academy of Sciences USA 97, 3850-3855. (Pubitemid 30226050)
54. Li YF, Cheng YF, Huang Y, Conti M, et al. (2011). Phosphodiesterase-4D knockout and RNAi-mediated knockdown enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. Journal of Neuroscience 31, 172-183.
55. Li YF, Huang Y, Amsdell SL, Xiao L, et al. (2009). Antidepressant-and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus. Neuropsychopharmacology 34, 2404-2419.
56. Lim GP, Yang F, Chu T, Chen P, et al. (2000). Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. Journal of Neuroscience 20, 5709-5714. (Pubitemid 30636898)
57. Lin HB, Yang XM, Li TJ, Cheng YF, et al. (2009). Memory deficits and neurochemical changes induced by C-reactive protein in rats : implication in Alzheimer's disease. Psychopharmacology (Berlin) 204, 705-714.
58. Lonze BE, Ginty DD (2002). Function and regulation of CREB family transcription factors in the nervous system. Neuron 35, 605-623. (Pubitemid 35229980)
59. Lukiw WJ, Bazan NG (2010). Inflammatory, apoptotic, and survival gene signaling in Alzheimer's disease. A review on the bioactivity of neuroprotectin D1 and apoptosis. Molecular Neurobiology 42, 10-16.
60. Luterman JD, Haroutunian V, Yemul S, Ho L, et al. (2000). Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Archives of Neurology 57, 1153-1160. (Pubitemid 30644662)
61. Malm T, Ort M, Tahtivaara L, Jukarainen N, et al. (2006). beta-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits. Proceedings of the National Academy of Sciences USA 103, 8852-8857. (Pubitemid 43878107)
62. Mattson MP (2004). Pathways towards and away from Alzheimer's disease. Nature 430, 631-639. (Pubitemid 39061671)
63. Maurice T, Lockhart BP, Su TP, Privat A (1996). Reversion of beta 25-35-amyloid peptide-induced amnesia by NMDA receptor-associated glycine site agonists. Brain Research 731, 249-253. (Pubitemid 26294934)
64. Mehlhorn G, Hollborn M, Schliebs R (2000). Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. International Society for Developmental Neuroscience 18, 423-431. (Pubitemid 30243072)
65. Monti B, Berteotti C, Contestabile A (2006). Subchronic rolipram delivery activates hippocampal CREB and Arc, enhances retention and slows down extinction of conditioned fear. Neuropsychopharmacology 31, 278-286. (Pubitemid 43113393)
66. Morris R (1984). Developments of a water-maze procedure for studying spatial learning in the rat. Journal of Neuroscience Methods 11, 47-60. (Pubitemid 14088970)
67. Mouri A, Zou LB, Iwata N, Saido TC, et al. (2006). Inhibition of neprilysin by thiorphan (i.c.v.) causes an accumulation of amyloid beta and impairment of learning and memory. Behavioural Brain Research 168, 83-91. (Pubitemid 43152056)
68. Mrak RE, Griffin WS (2001). Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiology of Aging 22, 903-908. (Pubitemid 34066557)
69. Naderi EH, Findley HW, Ruud E, Blomhoff HK, et al. (2009). Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation. Blood 114, 608-618.
70. Naganuma K, Omura A, Maekawara N, Saitoh M, et al. (2009). Discovery of selective PDE4B inhibitors. Bioorganic & Medicinal Chemistry Letters 19, 3174-3176.
71. Nakagawa S, Kim JE, Lee R, Malberg JE, et al. (2002). Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. Journal of Neuroscience 22, 3673-3682. (Pubitemid 37465772)
72. Naviglio S, Di Gesto D, Romano M, Sorrentino A, et al. (2009). Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biology and Therapy 8, 1183-1190.
73. O'Donnell JM, Zhang HT (2004). Antidepressant effects of inhibitors of cyclic AMP phosphodiesterase (PDE4). Trends in Pharmacological Sciences 25, 158-163. (Pubitemid 38264507)
74. O'Hare E, Weldon DT, Mantyh PW, Ghilardi JR, et al. (1999). Delayed behavioral effects following intrahippocampal injection of aggregated A beta (1-42). Brain Research 815, 1-10. (Pubitemid 29225218)
75. Olariu A, Tran MH, Yamada K, Mizuno M, et al. (2001). Memory deficits and increased emotionality induced by beta-amyloid (25-35) are correlated with the reduced acetylcholine release and altered phorbol dibutyrate binding in the hippocampus. Journal of Neural Transmission 108, 1065-1079. (Pubitemid 32802103)
76. Parachikova A, Agadjanyan MG, Cribbs DH, Blurton-Jones M, et al. (2007). Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiology of Aging 28, 1821-1833. (Pubitemid 47539700)
77. Parry GC, Mackman N (1997). Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. Journal of Immunology 159, 5450-5456. (Pubitemid 127470072)
78. Parvathenani LK, Buescher ES, Chacon-Cruz E, Beebe SJ (1998). Type I cAMP-dependent protein kinase delays apoptosis in human neutrophils at a site upstream of caspase-3. Journal of Biological Chemistry 273, 6736-6743. (Pubitemid 28160334)
79. Pasinetti GM (2001). Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia. Joural of Neuroscience Research 65, 471-476. (Pubitemid 32847139)
80. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates, 6th edn. San Diego, CA: Academic Press.
81. Perez-Torres S, Miro X, Palacios JM, Cortes R, et al. (2000). Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography. Comparison with monkey and rat brain. Journal of Chemical Neuroanatomy 20, 349-374. (Pubitemid 32162892)
82. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, et al. (1993). Neurodegeneration induced by beta-amyloid peptides in vitro : the role of peptide assembly state. Journal of Neuroscience 13, 1676-1687. (Pubitemid 23095409)
83. Rojo LE, Fernández JA, Maccioni AA, Jimenez JM, et al. (2008). Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Archives of Medical Research 39, 1-16. (Pubitemid 350192021)
84. Ruan CJ, Zhang L, Chen DH, Li Z, et al. (2010). Effects of trans-2,4-dimethoxystibene against the neurotoxicity induced by Abeta(25-35) both in vitro and in vivo. Neuroscience Research 67, 209-214.
85. Rutten K, Prickaerts J, Blokland A (2006). Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiology of Learning and Memory 85, 132-138. (Pubitemid 43247839)
86. Rutten K, Prickaerts J, Schaenzle G, Rosenbrock H, et al. (2008). Sub-chronic rolipram treatment leads to a persistent improvement in long-term object memory in rats. Neurobiology of Learning and Memory 90, 569-575.
87. Ryan KM, Phillips AC, Vousden KH (2001). Regulation and function of the p53 tumor suppressor protein. Current Opinion in Cell Biology 13, 332-337. (Pubitemid 32429498)
88. Sala C, Rudolph-Correia S, Sheng M (2000). Developmentally regulated NMDA receptor-dependent dephosphorylation of cAMP response element-binding protein (CREB) in hippocampal neurons. Journal of Neuroscience 20, 3529-3536. (Pubitemid 30266214)
89. Sanchez AJ, Puerta C, Ballester S, Gonzalez P, et al. (2005). Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 168, 13-20. (Pubitemid 41396399)
90. Satoh J, Tabunoki H, Arima K (2009). Molecular network analysis suggests aberrant CREB-mediated gene regulation in the Alzheimer disease hippocampus. Disease Markers 27, 239-52.
91. Sekut L, Yarnall D, Stimpson SA, Noel LS, et al. (1995). Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clinical & Experimental Immunology 100, 126-32.
92. Selkoe DJ (2000). Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Annals of the New York Academy of Sciences 924, 17-25. (Pubitemid 32050177)
93. Shaywitz AJ, Greenberg ME (1999). CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annual Review of Biochemistry 68, 821-861. (Pubitemid 29449210)
94. Smith DF (1990). Effects of lithium and rolipram enantiomers on locomotor activity in inbred mice. Pharmacology and Toxicology 66, 142-145. (Pubitemid 20105613)
95. Souness JE, Aldous D, Sargent C (2000). Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47, 127-162. (Pubitemid 30394536)
96. Sousa LP, Lopes F, Silva DM, Tavares LP, et al. (2010). PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaB-independent manner. Journal of Leukocyte Biology 87, 895-904.
97. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, et al. (1998). Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Molecular Cellular and Biology 18, 3509-3517. (Pubitemid 28240523)
98. Stepanichev MY, Moiseeva YV, Lazareva NA, Onufriev MV, et al. (2003). Single intracerebroventricular administration of amyloid-beta (25-35) peptide induces impairment in short-term rather than long-term memory in rats. Brain Research Bulletin 61, 197-205. (Pubitemid 36794278)
99. Suh YH, Checler F (2002). Amyloid precursor protein, presenilins, and alpha-synuclein : molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacological Reviews 54, 469-525.
100. Sun MK, Alkon DL (2002). Impairment of hippocampal CA1 heterosynaptic transformation and spatial memory by beta-amyloid(25-35). Journal of Neurophysiology 87, 2441-2449. (Pubitemid 34670715)
101. Suzuki Y, Nakabayashi Y, Nakata K, Reed JC, et al. (2001). X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and-7 in distinct modes. Journal of Biological Chemistry 276, 27058-27063.
102. Szelenyi J, Kiss JP, Puskas E, Szelenyi M, et al. (2000). Contribution of differently localized alpha 2-and beta-adrenoceptors in the modulation of TNF-alpha and IL-10 production in endotoxemic mice. Annals of the New York Academy of Sciences 917, 145-153.
103. Taguchi I, Oka K, Kitamura K, Sugiura M, et al. (1999). Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis. Inflammation Research 48, 380-385.
104. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG (1997). Phosphodiesterase (PDE)4 inhibitors : anti-inflammatory drugs of the future? Trends in Pharmacological Sciences 18, 164-171.
105. Tohda C, Matsumoto N, Zou K, Meselhy MR, et al. (2004). Abeta(25-35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, A metabolite of protopanaxadiol-type saponins. Neuropsychopharmacology 29, 860-868. (Pubitemid 38526786)
106. Tong L, Thornton PL, Balazs R, Cotman CW (2001). Beta-amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. Journal of Biological Chemistry 276, 17301-17306.
107. Townsend KP, Praticò D (2005). Novel therapeutic opportunities for Alzheimer's disease : focus on nonsteroidal anti-inflammatory drugs. Journal of the Federation of American Societies for Experimental Biology 19, 1592-1601. (Pubitemid 41429517)
108. Tully T, Bourtchouladze R, Scott R, Tallman J (2003). Targeting the CREB pathway for memory enhancers. Nature Reviews Drug Discovery 2, 267-277. (Pubitemid 37361685)
109. Tusi SK, Ansari N, Amini M, Amirabad AD, et al. (2010). Attenuation of NF-kappaB and activation of Nrf2 signaling by 1,2,4-triazine derivatives, protects neuron-like PC12 cells against apoptosis. Apoptosis 15, 738-751.
110. Um MY, Choi WH, Aan JY, Kim SR, et al. (2006). Protective effect of Polygonum multiflorum Thunb on amyloid beta-peptide 25-35 induced cognitive deficits in mice. Journal of Ethnopharmacology 104, 144-148.
111. Vecsey CG, Baillie GS, Jaganath D, Havekes R, et al. (2009). Sleep deprivation impairs cAMP signalling in the hippocampus. Nature 461, 1122-1125.
112. Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, et al. (2002). Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proceedings of the National Academy of Sciences USA 99, 13217-13221.
113. Vollmar P, Kullmann JS, Thilo B, Claussen MC, et al. (2010). Active immunization with amyloid-b 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system. Journal of Immunology 185, 6338-6347.
114. Wang D, Li H, Yuan H, Zheng M, et al. (2005). Humanin delays apoptosis in K562 cells by downregulation of P38 MAP kinase. Apoptosis 10, 963-971. (Pubitemid 41285576)
115. Wang XH, Li L, Hölscher C, Pan YF, et al. (2010). Val8-glucagon-like peptide-1 protects against Ab1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 170, 1239-4128.
116. Wang XY, Chen J, Zhang JT (2001). Effect of ginsenoside Rg1 on learning and memory impairment induced by beta-amyloid peptide(25-35) and its mechanism of action. Yao Xue Xue Bao 36, 1-4.
117. Yamada K, Tanaka T, Han D, Senzaki K, et al. (1999). Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats : implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. European Journal of Neuroscience 11, 83-90. (Pubitemid 29012313)
118. Yang X, Askarova S, Lee JC (2010). Membrane biophysics and mechanics in Alzheimer's disease. Molecular Neurobiology 41, 138-148.
119. Yang Y, Fang S, Jensen JP, Weissman AM, et al. (2000). Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288, 874-877. (Pubitemid 30257739)
120. Yao M, Nguyen TV, Pike CJ (2007). Estrogen regulates Bcl-w and Bim expression : role in protection against beta-amyloid peptide-induced neuronal death. Journal of Neuroscience 27, 1422-1433.
121. Zeng Y, Zhao D, Xie CW (2010). Neurotrophins enhance CaMKII activity and rescue amyloid-b-induced deficits in hippocampal synaptic plasticity. Journal of Alzheimer's Disease 21, 823-83.
122. Zhang HT (2009). Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Current Pharmaceutical Design 15, 1688-1698.
123. Zhang HT (2010). Phosphodiesterase Targets for Cognitive Dysfunction and Schizophrenia-a New York Academy of Sciences Meeting. Investigational Drugs 13, 166-168.
124. Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, et al. (2000). Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 23, 198-204. (Pubitemid 30406904)
125. Zhang HT, Huang Y, Jin SLC, Frith SA, et al. (2002). Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27, 587-595.
126. Zhang HT, Huang Y, Masood A, Stolinski LR, et al. (2008). Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 33, 1611-1623. (Pubitemid 351684706)
127. Zhang HT, Huang Y, Suvarna NU, Deng C, et al. (2005). Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology (Berlin) 179, 613-619. (Pubitemid 40674762)
128. Zhang HT, O'Donnell JM (2000). Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology (Berlin) 150, 311-316. (Pubitemid 30447851)
129. Zhang HT, Zhao Y, Huang Y, Dorairaj NR, et al. (2004). Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology 29, 1432-1439. (Pubitemid 38982235)
130. Zhang JM, Wu MN, Qi JS, Qiao JT (2006). Amyloid beta-protein fragment 31-35 suppresses long-term potentiation in hippocampal CA1 region of rats in vivo. Synapse 60, 307-313.